• Cellvizio®
    • Overview
    • Education
    • Economics
    • Indications
      • Gastroenterology
        • Barrett’s Esophagus
        • Pancreatic Cysts
        • Gastric Disease
        • Inflammatory Bowel Diseases
        • Irritable Bowel Syndrome – Food Intolerance
        • Bilio-Pancreatic Strictures
        • Colorectal Lesions
      • Pulmonology
        • Lung Nodules
        • Lung Transplant
      • Urology
  • Investors
    • Overview
    • Events and Presentations
    • Financials
    • Governance
  • About Us
    • Our Story
    • Team
      • Board of Directors
      • Leadership Team
    • Join Us
    • Commercial Network
  • Newsroom
    • News
    • Events
    • Press Coverage
  • US
    • INT
    • FR
Mauna Kea Technologies Reports First Half 2025 Revenue 

Mauna Kea Technologies Reports First Half 2025 Revenue 

by Elizabeth | Jul 28, 2025 | News

On Constant Currency Basis (CER), U.S. sales up +17% Y/Y in H1 and +23% in Q2  Record U.S. sales productivity despite ongoing safeguard procedure  Total revenue down 5% amid weaker EMEA and ROW sales results  Further steps taken to improve Mauna Kea...
Mauna Kea Technologies Enters Australian Market with Endotherapeutics Partnership 

Mauna Kea Technologies Enters Australian Market with Endotherapeutics Partnership 

by Elizabeth | Jul 24, 2025 | News

Leveraging strong momentum for the CellTolerance® application, Mauna Kea Technologies is expanding into new geographies with high growth potential  Regulatory clearance in Australia (TGA) expected in the coming months  Paris and Boston, July 24, 2025 – 5:45 p.m....
Mauna Kea Technologies Reports First Half 2025 Revenue 

Mauna Kea Technologies Strengthens its Leading Role in the AI-based Endomicroscopic Imaging Ecosystem with its 14th Patent Granted in the U.S. 

by Elizabeth | Jul 21, 2025 | News

14th U.S. AI patent awarded complementing a comprehensive portfolio of AI-related intellectual property  An ecosystem built around the Cellvizio® platform, enabling partners to develop advanced AI models  Paris and Boston, July 21, 2025 – 5:45 p.m. CEST – Mauna...
Mauna Kea Technologies Enters Australian Market with Endotherapeutics Partnership 

Mauna Kea Technologies Congratulates Stanford Health Care on Completing 100 Food Intolerance Cases with Cellvizio 

by Elizabeth | Jul 15, 2025 | News

Clinical team at Stanford Health Care achieved the CellTolerance 100-case milestone with the Cellvizio® platform in less than 6 months  The CellTolerance® test offers IBS patients a way to detect, understand, and treat food intolerance by revealing cellular-level...
United European Gastroenterology (UEG) Week 2025 Berlin, Germany

United European Gastroenterology (UEG) Week 2025 Berlin, Germany

by Elizabeth | Jul 12, 2025 | Events

United European Gastroenterology (UEG) Week is the largest and most prestigious GI meeting in Europe.It combines world class scientific research, invited lectures by leading minds in gastroenterology and an excellent Postgraduate Teaching Programme.Multidisciplinarity...
« Older Entries

Articles récents

  • Mauna Kea Technologies Reports First Half 2025 Revenue 
  • Mauna Kea Technologies Enters Australian Market with Endotherapeutics Partnership 
  • Mauna Kea Technologies Strengthens its Leading Role in the AI-based Endomicroscopic Imaging Ecosystem with its 14th Patent Granted in the U.S. 
  • Mauna Kea Technologies Congratulates Stanford Health Care on Completing 100 Food Intolerance Cases with Cellvizio 
  • United European Gastroenterology (UEG) Week 2025 Berlin, Germany

Commentaires récents

No comments to show.

Company Info

About Us

Join Us

Contact Us

Legal

Legal notice

Privacy policy

Cookie policy

Our websites

Cellvizio.net

cell-tolerance.com

Diagnosingbarretts.org

Diagnosingpancreaticcysts.org

Follow us

  • Follow
  • Follow
  • Follow
  • Follow
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}